Therapeutic Lowering of C-Reactive Protein.

Area of Science:

• Immunology
• Biochemistry
• Pathology

Background:

• C-reactive protein (CRP) is a key inflammatory marker, typically elevated during disease.
• Its clinical utility in monitoring inflammation is well-established.
• However, CRP's biological functions at baseline levels are often overlooked.

Purpose of the Study:

• To review the history, biosynthesis, and clinical use of CRP.
• To present evidence for CRP's biological activity at baseline levels.
• To explore therapeutic strategies targeting baseline CRP.

Main Methods:

• Review of existing literature on CRP.
• Analysis of studies using human CRP transgenic and CRP knockout mice.
• Examination of evidence from animal models of arthritis, neointimal hyperplasia, and acute kidney injury.

Main Results:

• CRP is synthesized at baseline and during acute phase responses.
• Studies demonstrate significant biological effects of CRP even at baseline levels.
• Evidence from various animal models supports baseline CRP's role in disease processes.

Conclusions:

• CRP exerts important biological effects independent of elevated levels.
• Baseline CRP levels may be a viable therapeutic target.
• Targeting baseline CRP could offer new treatment strategies for diseases including cancer.